Hormone Receptor Positive Tumor Not Yet Recruiting Phase 2 Trials for Trastuzumab (DB00072)

IndicationStatusPhase
DBCOND0075370 (Hormone Receptor Positive Tumor)Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03910712Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBCTreatment